Skip to main
DBD

DBD Stock Forecast & Price Target

DBD Analyst Ratings

Based on 2 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Diebold Nixdorf Inc has demonstrated strong financial performance, with order entry for 2025 increasing approximately 17% year-over-year, driven by robust demand in both banking and retail segments, indicating a healthy growth trajectory. The banking segment reported product revenues of $381 million, reflecting a 20% year-over-year increase and total revenues of $798 million, which rose 16% quarter-over-quarter and 11% year-over-year, showcasing the company's solid revenue generation capabilities. Furthermore, the company has consistently generated positive free cash flow, with CQ4 free cash flow reaching $196 million—a 5.4% increase from the prior year—marking the first instance of positive free cash flow across all four quarters, which bodes well for future financial stability and growth.

Bears say

The financial outlook for Diebold Nixdorf Inc. appears negative due to anticipated declines in backlog and quarterly results, reflecting typical seasonality. Additionally, the company may face risks that could negatively impact profitability, such as tariff-related costs, supply chain disruptions, and lower-than-expected demand for service upgrades in its primary Banking segment. Liquidity issues, indicated by a low average daily trading volume, further exacerbate financial uncertainty, potentially limiting investor interest and share performance.

DBD has been analyzed by 2 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Diebold Nixdorf Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Diebold Nixdorf Inc (DBD) Forecast

Analysts have given DBD a Buy based on their latest research and market trends.

According to 2 analysts, DBD has a Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $100, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $100, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Diebold Nixdorf Inc (DBD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.